- Home
- BELFB vs PRTA Comparison
BELFB vs PRTA Comparison
Compare BELFB & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BELFB
- PRTA
- Stock Information
- Founded
- BELFB 1949
- PRTA 2012
- Country
- BELFB United States
- PRTA Ireland
- Employees
- BELFB N/A
- PRTA N/A
- Industry
- BELFB
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- BELFB
- PRTA Health Care
- Exchange
- BELFB Nasdaq
- PRTA Nasdaq
- Market Cap
- BELFB 865.9M
- PRTA 809.8M
- IPO Year
- BELFB N/A
- PRTA N/A
- Fundamental
- Price
- BELFB $98.13
- PRTA $6.16
- Analyst Decision
- BELFB Strong Buy
- PRTA Buy
- Analyst Count
- BELFB 4
- PRTA 9
- Target Price
- BELFB $95.75
- PRTA $27.67
- AVG Volume (30 Days)
- BELFB 162.4K
- PRTA 1.8M
- Earning Date
- BELFB 07-23-2025
- PRTA 08-07-2025
- Dividend Yield
- BELFB 0.29%
- PRTA N/A
- EPS Growth
- BELFB N/A
- PRTA N/A
- EPS
- BELFB 3.42
- PRTA N/A
- Revenue
- BELFB $558,940,000.00
- PRTA $137,935,000.00
- Revenue This Year
- BELFB $18.21
- PRTA N/A
- Revenue Next Year
- BELFB $7.91
- PRTA $119.20
- P/E Ratio
- BELFB $28.73
- PRTA N/A
- Revenue Growth
- BELFB N/A
- PRTA 54.55
- 52 Week Low
- BELFB $58.00
- PRTA $4.32
- 52 Week High
- BELFB $98.43
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- BELFB 75.23
- PRTA 53.00
- Support Level
- BELFB $90.52
- PRTA $5.64
- Resistance Level
- BELFB $95.00
- PRTA $6.36
- Average True Range (ATR)
- BELFB 3.46
- PRTA 0.38
- MACD
- BELFB 0.98
- PRTA 0.25
- Stochastic Oscillator
- BELFB 94.46
- PRTA 87.23
About BELFB Bel Fuse Inc. Class B
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).